IONS Stock Price Today (October 2026) — Ionis Pharmaceuticals, Inc. Analysis & Key Metrics 2026-10-07
Ionis Pharmaceuticals, Inc. (IONS) is trading at $44.16, up 0.36% today (as of October 2026). The stock continues to show pressure below major moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $83.64 (89.4% upside).
- Volatility is moderate (29.58% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: declining revenue trends (-40.70% YoY) alongside competitive pressures in the Biotechnology space.
IONS Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Ionis Pharmaceuticals, Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $7.43B
P/E Ratio
Forward P/E: N/A
Revenue Growth
Year over Year
Analyst Target
+89.4% upside potential
Key Investor Questions About IONS
What investors need to know before buying
Based on current market data, IONS presents a neutral technical setup with challenging fundamentals.
- Technicals say: Neutral (RSI 34.23)
- Fundamentals say: Challenging (declining revenue trends)
IONS's growth trajectory depends on its ability to expand within the Biotechnology sector while managing margin pressures.
- Future growth will depend on performance in core Biotechnology operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for IONS investors include debt exposure and competitive dynamics in the Biotechnology industry.
- $2.19B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Biotechnology.
52-Week Trading Range
Over the past year, IONS stock traded between $43.01 and $86.74 and currently trades near the low end of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 29.58% annualized volatility and β=0.46, the stock exhibits low sensitivity to market moves—making IONS suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
Lower institutional support combined with high short selling points to negative sentiment.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Ionis Pharmaceuticals (IONS) Stock Looks Pricey On Its 45% YTD Slide
Ionis Pharmaceuticals has had a rough run so far this year, even as fresh clinical results have put its drug pipeline in the spotlight. With the share price under pressure, the real issue for investors is how well the current valuation lines up with the sales its business is generating and may be able to support over time. The stock is down about 45.0% year to date. This puts a sharp spotlight on whether today's market value still lines up with what Ionis can justify through its sales...
Failure of Novartis’ Pelacarsen Could Reshape the Lp(a) Race for CRISPR and Ionis
Novartis AG’s (NYSE:NVS) Phase 3 Lp(a)HORIZON setback carries implications beyond the Swiss drugmaker. Pelacarsen significantly lowered lipoprotein(a), or Lp(a), but failed to produce a statistically significant reduction in major cardiovascular events, according to the information provided. READ ALSO: Can a Tagrisso Combination Strengthen AstraZeneca’s Path to $80 Billion? That disconnect matters for companies developing other […]
Roche, Ionis RNA drug scores in kidney disease study
The results position Roche to bring a new kind of medicine to market for IgA nephropathy, a disease that’s drawn considerable attention of late from drugmakers.
Ionis Delivers Positive Late-Stage Results for Two Partnered Drugs
IONS posts positive phase III results for two partnered drugs, with ulefnersen meeting its ALS endpoint and sefaxersen cutting proteinuria.
Ionis and Roche Advance First RNA-Targeted Therapy for Autoimmune Kidney Disease
Ionis Pharmaceuticals Inc. (NASDAQ:IONS) and licensing partner Roche Holdings AG (OTC:RHHBY) on Wednesday shared prespecified interim outcomes from their ongoing Phase 3 IMAgINATION trial of investigational sefaxersen in adults diagnosed with primary IgA nephropathy (IgAN). "These interim phase 3 results show the clinical potential of sefaxersen to modify a key surrogate endpoint of kidney function in people with IgA nephropathy’’ said Levi Garraway, Roche’s Chief Medical Officer and Head of Glo
Beyond Meta, Cathie Wood’s ARKG Loads Up On These 4 Biotech Names
ARK’s latest portfolio moves spotlighted IONS, VCYT, SCTX, and BEAM as the firm increased its biotech exposure alongside a major Meta purchase.
Investors Dumped Ionis Pharmaceuticals Stock -- But Wall Street Hasn't Budged From Its Bullish Outlook
Shares of Ionis are down more than 40% so far this year.
Ionis Pharmaceuticals Eyes TRYNGOLZA Growth as Pipeline Faces Cardio Setbacks
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia outlined recent regulatory wins, commercial-launch progress and several pipeline updates at the Morgan Stanley Global Healthcare Conference, while acknowledging setbacks in late-stage cardiovascular studies. Monia said the company has secured two
Ionis Pharmaceuticals (IONS) Dropped, What Is Behind The Latest Attention?
Ionis Pharmaceuticals (IONS) is back in focus after partner Novartis reported that the pivotal Phase 3 Lp(a)HORIZON trial of pelacarsen failed to reduce major cardiovascular events despite sharply lowering Lp(a) levels. The pelacarsen setback comes after a sharp reset in sentiment. Ionis Pharmaceuticals has posted a 7-day share price return of negative 15.99% and a 30-day share price return of negative 21.59%. Despite this, the company still has a 5-year total shareholder return of 25.67%,...
Novartis (NVS) and Ionis (IONS)’ Big Cholesterol Bet Comes Up Short in Late-Stage Trial
On September 5, 2026, Reuters reported that pelacarsen, an experimental drug from Novartis AG (NYSE:NVS) and partner Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) meant to lower a cholesterol-carrying particle called Lp(a), failed to reduce heart attacks, strokes and related cardiovascular events in the Lp(a)HORIZON trial, which enrolled more than 8,000 patients. The drug did lower Lp(a) levels […]
Explore More Analysis for IONS
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Oct 27, 2026 (before the open, usually)
Frequently Asked Questions
Common investor questions about Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (IONS) is currently trading at $44.16. The RSI (14-day) is at 34.2, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $83.64 implies 89.4% upside from current levels. Volatility is moderate at 29.6% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Ionis Pharmaceuticals, Inc. (IONS): The trailing P/E ratio is not available (the company may not be profitable). Price-to-Book is 19.37. Price-to-Sales is 9.78. Valuation should be compared to Biotechnology industry peers for context, as different sectors trade at different multiples.
Based on 22 analysts covering IONS, the consensus price target is $83.64. This represents a 89.4% upside from the current price of $44.16. The range spans from a low target of $54.00 to a high target of $105.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Ionis Pharmaceuticals, Inc. (IONS) does not currently pay a regular dividend. The company may be reinvesting profits into growth initiatives, or may not yet be profitable enough to distribute earnings to shareholders.
Key risks for Ionis Pharmaceuticals, Inc. (IONS) investors include: 1. Moderate volatility (29.6% annualized)—price swings are notable. 2. Elevated debt levels (debt-to-equity of 4.98x) which could pressure margins in a rising rate environment. 3. The company is not currently profitable on a trailing basis, which creates earnings uncertainty. 4. Declining revenue (-40.7% YoY), indicating potential business headwinds. 5. Elevated short interest (16.6% of float) suggests significant bearish sentiment. 6. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 7. Biotechnology sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Ionis Pharmaceuticals, Inc.'s (IONS) current debt and financial health profile: Total debt stands at $2.19B. The debt-to-equity ratio is 4.98x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 7.89, indicating strong short-term liquidity. The quick ratio is 6.85. The company holds $2.10B in cash and equivalents. Free cash flow is negative at -$346.76M, which could limit the company's ability to manage debt obligations.